Delving into the Latest Updates on Edinburgh Molecular Imaging Ltd. with Synapse

概览

疾病领域	数量

肿瘤	3
感染	2

排名前五的药物类型	数量

其他体内诊断药物	4
合成多肽	3
小分子化药	2
多肽偶联药物（PDC）	1
化学药	1

排名前五的靶点	数量

c-Met(肝细胞生长因子受体)	4

关联

12

项与 Edinburgh Molecular Imaging Ltd. 相关的药物

EMI-137

靶点

c-Met

作用机制

c-Met调节剂

在研机构

GE Healthcare, Inc. [+1]

原研机构

GE Healthcare, Inc.

在研适应症

诊断试剂

非在研适应症

巴雷特食管 [+10]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

EMI-400

靶点-

作用机制

诊断染料分子

在研机构

Edinburgh Molecular Imaging Ltd.初创企业

原研机构

Edinburgh Molecular Imaging Ltd.初创企业

在研适应症

肺纤维化

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

EMI-350

靶点-

作用机制

诊断染料分子

在研机构

Edinburgh Molecular Imaging Ltd.初创企业

原研机构

Edinburgh Molecular Imaging Ltd.初创企业

在研适应症

呼吸道感染

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

3

项与 Edinburgh Molecular Imaging Ltd. 相关的临床试验

NCT03360461 / Completed临床2期IIT

Intraoperative Imaging of Colon Cancer Using a Fluorescent Peptide (EMI-137) Against the c-Met Receptor

EMI-137 in laparoscopic colonic resections is a single-centre stage IIa developmental study.
Ten adult participants with a diagnosis of colon adenocarcinoma undergoing laparoscopic colonic will be recruited to the trial. Participants will receive a single intravenous dose of the IMP - EMI-137 1 to 3 hours before surgery. The ability of EMI-137 to produce visible intra-operative fluorescence of primary colon cancer and lymph node metastases will be explored and evaluated.

开始日期2018-02-14

申办/合作机构

University of Leeds

[+1]

EUCTR2016-002827-27-NL / Not yet recruiting临床2期

A Phase IIb, Open Label Study for the Detection of Dysplastic Colorectal Polyps during Colonoscopy after EMI-137 Injection in Patients with High Suspicion of Colorectal Cancer. - EMI-137 for detection of dysplastic colorectal polyps

开始日期2016-12-16

申办/合作机构

Edinburgh Molecular Imaging Ltd.初创企业

NL-OMON47367 / Completed临床2期

A Phase IIb, Open Label Study for the Detection of Dysplastic Colorectal Polyps during Colonoscopy after EMI-137 Injection in Patients with High Suspicion of Colorectal Cancer. - EMI-137 for detection of dysplastic colorectal polyps

开始日期2016-11-01

申办/合作机构

Edinburgh Molecular Imaging Ltd.初创企业

100 项与 Edinburgh Molecular Imaging Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Edinburgh Molecular Imaging Ltd. 相关的专利（医药）

登录后查看更多信息

3

项与 Edinburgh Molecular Imaging Ltd. 相关的文献（医药）

2020-06-01·European Heart Journal - Cardiovascular Imaging1区 · 医学

Non-invasive in vivo imaging of acute thrombosis: development of a novel factor XIIIa radiotracer

1区 · 医学

Article

作者: Dweck, Marc R ; Alcaide Corral, Carlos ; Macaskill, Mark G ; Wilson, Simon ; Walton, Tashfeen ; Andrews, Jack P M ; Tavares, Adriana A S ; Lucatelli, Christophe ; Wilson, Ian ; Hadoke, Patrick W F ; MacNaught, Gillian ; Portal, Christophe ; Newby, David E

AbstractAimsCardiovascular thrombosis is responsible a quarter of deaths annually worldwide. Current imaging methods for cardiovascular thrombosis focus on anatomical identification of thrombus but cannot determine thrombus age or activity. Molecular imaging techniques hold promise for identification and quantification of thrombosis in vivo. Our objective was to assess a novel optical and positron-emitting probe targeting Factor XIIIa (ENC2015) as biomarker of active thrombus formation.Methods and resultsOptical and positron-emitting ENC2015 probes were assessed ex vivo using blood drawn from human volunteers and passed through perfusion chambers containing denuded porcine aorta as a model of arterial injury. Specificity of ENC2015 was established with co-infusion of a factor XIIIa inhibitor. In vivo18F-ENC2015 biodistribution, kinetics, radiometabolism, and thrombus binding were characterized in rats. Both Cy5 and fluorine-18 labelled ENC2015 rapidly and specifically bound to thrombi. Thrombus uptake was inhibited by a factor XIIIa inhibitor. 18F-ENC2015 remained unmetabolized over 8 h when incubated in ex vivo human blood. In vivo, 42% of parent radiotracer remained in blood 60 min post-administration. Biodistribution studies demonstrated rapid clearance from tissues with elimination via the urinary system. In vivo,18F-ENC2015 uptake was markedly increased in the thrombosed carotid artery compared to the contralateral patent artery (mean standard uptake value ratio of 2.40 vs. 0.74, P < 0.0001).Conclusion ENC2015 rapidly and selectively binds to acute thrombus in both an ex vivo human translational model and an in vivo rodent model of arterial thrombosis. This probe holds promise for the non-invasive identification of thrombus formation in cardiovascular disease.

2017-04-01·Heart1区 · 医学

Cardiac α_Vβ₃integrin expression following acute myocardial infarction in humans

1区 · 医学

Article

作者: Lucatelli, Christophe ; Vickers, Anna ; Mirsadraee, Saeed ; Connell, Martin ; Neale, Anoushka ; Rudd, James H F ; Fletcher, Alison ; Moles, Catriona ; Dweck, Marc R ; Wilson, Ian ; Newby, David E ; Vesey, Alex T ; Jenkins, William S A ; Stirrat, Colin ; van Beek, Edwin J R ; Pawade, Tania

OBJECTIVEMaladaptive repair contributes towards the development of heart failure following myocardial infarction (MI). The α_vβ₃ integrin receptor is a key mediator and determinant of cardiac repair. We aimed to establish whether α_vβ₃ integrin expression determines myocardial recovery following MI.METHODS¹⁸F-Fluciclatide (a novel α_vβ₃-selective radiotracer) positron emission tomography (PET) and CT imaging and gadolinium-enhanced MRI (CMR) were performed in 21 patients 2 weeks after ST-segment elevation MI (anterior, n=16; lateral, n=4; inferior, n=1). CMR was repeated 9 months after MI. 7 stable patients with chronic total occlusion (CTO) of a major coronary vessel and nine healthy volunteers underwent a single PET/CT and CMR.RESULTS¹⁸F-Fluciclatide uptake was increased at sites of acute infarction compared with remote myocardium (tissue-to-background ratio (TBR_mean) 1.34±0.22 vs 0.85±0.17; p<0.001) and myocardium of healthy volunteers (TBR_mean 1.34±0.22 vs 0.70±0.03; p<0.001). There was no ¹⁸F-fluciclatide uptake at sites of established prior infarction in patients with CTO, with activity similar to the myocardium of healthy volunteers (TBR_mean 0.71±0.06 vs 0.70±0.03, p=0.83). ¹⁸F-Fluciclatide uptake occurred at sites of regional wall hypokinesia (wall motion index≥1 vs 0; TBR_mean 0.93±0.31 vs 0.80±0.26 respectively, p<0.001) and subendocardial infarction. Importantly, although there was no correlation with infarct size (r=0.03, p=0.90) or inflammation (C reactive protein, r=-0.20, p=0.38), ¹⁸F-fluciclatide uptake was increased in segments displaying functional recovery (TBR_mean 0.95±0.33 vs 0.81±0.27, p=0.002) and associated with increase in probability of regional recovery.CONCLUSION¹⁸F-Fluciclatide uptake is increased at sites of recent MI acting as a biomarker of cardiac repair and predicting regions of recovery.TRIAL REGISTRATION NUMBERNCT01813045; Post-results.

Diagnostics4区 · 医学

CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy

4区 · 医学

ArticleOA

作者: van der Valk, Maxime ; Linders, Daan ; Vahrmeijer, Alexander ; Tummers, Willemieke ; Schaap, Dennis ; Deken, Marion ; Farina Sarasqueta, Arantza ; van Lijnschoten, Gesina ; Kuppen, Peter ; van de Velde, Cornelis ; Hilling, Denise ; Bhairosingh, Shadhvi ; Zonoobi, Elham ; Sier, Cornelis

Rectal cancer patients with a complete response after neoadjuvant therapy can be monitored with a watch-and-wait strategy. However, regrowth rates indicate that identification of patients with a pathological complete response (pCR) remains challenging. Targeted near-infrared fluorescence endoscopy is a potential tool to improve response evaluation. Promising tumor targets include carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), integrin αvβ6, and urokinase-type plasminogen activator receptor (uPAR). To investigate the applicability of these targets, we analyzed protein expression by immunohistochemistry and quantified these by a total immunostaining score (TIS) in tissue of rectal cancer patients with a pCR. CEA, EpCAM, αvβ6, and uPAR expression in the diagnostic biopsy was high (TIS > 6) in, respectively, 100%, 100%, 33%, and 46% of cases. CEA and EpCAM expressions were significantly higher in the diagnostic biopsy compared with the corresponding tumor bed (p < 0.01). CEA, EpCAM, αvβ6, and uPAR expressions were low (TIS < 6) in the tumor bed in, respectively, 93%, 95%, 85%, and 62.5% of cases. Immunohistochemical evaluation shows that CEA and EpCAM could be suitable targets for response evaluation after neoadjuvant treatment, since expression of these targets in the primary tumor bed is low compared with the diagnostic biopsy and adjacent pre-existent rectal mucosa in more than 90% of patients with a pCR.

100 项与 Edinburgh Molecular Imaging Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Edinburgh Molecular Imaging Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

1

3

临床前

临床1期

3

1

临床2期

其他

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

EMI-137 ( c-Met )	诊断试剂更多	临床2期
EMI-300	呼吸道感染更多	临床1期
EMI-350	呼吸道感染更多	临床1期
EMI-400	肺纤维化更多	临床1期
EMP-102 ( c-Met )	实体瘤更多	临床前